simone Giannecchini

List of Publications by Year
in descending order

64 papers	1,073 citations	393982 19 h-index	552369 26 g-index
65 all docs	65 docs citations	65 times ranked	1437 citing authors

#	Article	IF	Citations
1	Screening of the essential oil effects on human H1N1 influenza virus infection: an <i>in vitro</i> study in MDCK cells. Natural Product Research, 2022, 36, 3149-3152.	1.0	5
2	MALDI-TOF mass spectrometry of saliva samples as a prognostic tool for COVID-19. Journal of Oral Microbiology, 2022, 14, 2043651.	1.2	6
3	Lack of direct association between oral mucosal lesions and SARS-CoV- 2 in a cohort of patients hospitalised with COVID-19. Journal of Oral Microbiology, 2022, 14, 2047491.	1.2	5
4	Quantification of torque teno virus (TTV) DNA in saliva and plasma samples in patients at short time before and after kidney transplantation. Journal of Oral Microbiology, 2022, 14, 2008140.	1.2	4
5	Use of saliva and RTâ€PCR screening for SARSâ€CoVâ€2 variants of concern: Surveillance and monitoring. Journal of Medical Virology, 2022, 94, 4518-4521.	2.5	9
6	Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19. Virology Journal, 2022, 19, 79.	1.4	5
7	SARSâ€CoVâ€2: What can saliva tell us?. Oral Diseases, 2021, 27, 746-747.	1.5	33
8	COVID-19 salivary signature: diagnostic and research opportunities. Journal of Clinical Pathology, 2021, 74, 344-349.	1.0	62
9	Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19. Journal of Oral Microbiology, 2021, 13, 1858002.	1.2	34
10	Detection of polyomavirus microRNA-5p expression in saliva shortly after kidney transplantation. Journal of Oral Microbiology, 2021, 13, 1898838.	1.2	2
11	Volatiles and Antifungalâ€“Antibacterialâ€“Antiviral Activity of South African Salvia spp. Essential Oils Cultivated in Uniform Conditions. Molecules, 2021, 26, 2826.	1.7	11
12	West Nile Virus Seroprevalence in the Italian Tuscany Region from 2016 to 2019. Pathogens, 2021, 10, 844.	1.2	2
13	Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses. Journal of Medicinal Chemistry, 2020, 63, 9876-9887.	2.9	7
14	Torque teno virus microRNA detection in cerebrospinal fluids of patients with neurological pathologies. Journal of Clinical Virology, 2020, 133, 104687.	1.6	4
15	Evidence of the Mechanism by Which Polyomaviruses Exploit the Extracellular Vesicle Delivery System during Infection. Viruses, 2020, 12, 585.	1.5	16
16	Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples. Journal of Clinical Virology, 2020, 128, 104435.	1.6	14
17	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection. Journal of Medicinal Chemistry, 2019, 62, 2333-2347.	2.9	49
18	Multiple Signatures of the JC Polyomavirus in Paired Normal and Altered Colorectal Mucosa Indicate a Link with Human Colorectal Cancer, but Not with Cancer Progression. International Journal of Molecular Sciences, 2019, 20, 5965.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004â€“2017. BMC Infectious Diseases, 2019, 19, 990.	1.3	34
20	Polyomavirus microRNA in saliva reveals persistent infectious status in the oral cavity. Virus Research, 2018, 249, 1-7.	1.1	15
21	Torquetenovirus detection in exosomes enriched vesicles circulating in human plasma samples. Virology Journal, 2018, 15, 145.	1.4	23
22	BK Polyomavirus MicroRNA Levels in Exosomes Are Modulated by Non-Coding Control Region Activity and Down-Regulate Viral Replication When Delivered to Non-Infected Cells Prior to Infection. Viruses, 2018, 10, 466.	1.5	15
23	Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects. Experimental Gerontology, 2018, 112, 103-111.	1.2	25
24	Polyomavirus microRNAs circulating in biological fluids during viral persistence. Reviews in Medical Virology, 2017, 27, e1927.	3.9	24
25	Utility of droplet digital PCR for the quantitative detection of polyomavirus JC in clinical samples. Journal of Clinical Virology, 2016, 82, 70-75.	1.6	13
26	Polyomavirus JC microRNA expression after infection in vitro. Virus Research, 2016, 213, 269-273.	1.1	10
27	Investigation on torquetenovirus (TTV) microRNA transcriptome in vivo. Virus Research, 2016, 217, 18-22.	1.1	18
28	Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e58.	3.1	6
29	Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. Journal of NeuroVirology, 2015, 21, 666-670.	1.0	25
30	Small RNAs targeting the 5â€² end of the viral polymerase gene segments specifically interfere with influenza type A virus replication. Journal of Biotechnology, 2015, 210, 85-90.	1.9	5
31	The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML. Journal of Clinical Virology, 2015, 70, 1-6.	1.6	23
32	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. Antiviral Research, 2014, 108, 94-103.	1.9	13
33	Reassortment ability of the 2009 pandemic H1N1 influenza virus with circulating human and avian influenza viruses: Public health risk implications. Virus Research, 2013, 175, 151-154.	1.1	12
34	Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab. Journal of NeuroVirology, 2012, 18, 55-61.	1.0	10
35	Packaging signals in the 5â€²-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. Antiviral Research, 2011, 92, 64-72.	1.9	15
36	Molecular adaptation of an H7N3 wild duck influenza virus following experimental multiple passages in quail and turkey. Virology, 2010, 408, 167-173.	1.1	28

#	ARTICLE	IF	CITATIONS
37	Increased Pathogenicity and Shedding in Chickens of a Wild Birdâ€"Origin Low Pathogenicity Avian Influenza Virus of the H7N3 Subtype Following MultipleIn VivoPassages in Quail and Turkey. Avian Diseases, 2010, 54, 555-557.	0.4	16
38	Oligonucleotides derived from the packaging signal at the 5â€² end of the viral PB2 segment specifically inhibit influenza virus in vitro. Archives of Virology, 2009, 154, 821-832.	0.9	19
39	Antibodies Generated in Cats by a Lipopeptide Reproducing the Membrane-Proximal External Region of the Feline Immunodeficiency Virus Transmembrane Enhance Virus Infectivity. Vaccine Journal, 2007, 14, 944-951.	3.2	12
40	Role of Env in Resistance of Feline Immunodeficiency Virus (FIV)-Infected Cats to Superinfection by a Second FIV Strain as Determined by Using a Chimeric Virus. Journal of Virology, 2007, 81, 10474-10485.	1.5	4
41	Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules. Virus Research, 2007, 129, 241-245.	1.1	8
42	Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the feline immunodeficiency virus and its lipoylated analogue in micellar systems. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1653-1661.	1.4	13
43	Development of Antiviral Fusion Inhibitors: Short Modified Peptides Derived from the Transmembrane Glycoprotein of Feline Immunodeficiency Virus. ChemBioChem, 2006, 7, 774-779.	1.3	19
44	Comparison of in vitro replication features of H7N3 influenza viruses from wild ducks and turkeys: potential implications for interspecies transmission. Journal of General Virology, 2006, 87, 171-175.	1.3	36
45	Vaccination with an Inactivated Virulent Feline Immunodeficiency Virus Engineered To Express High Levels of Env. Journal of Virology, 2005, 79, 1954-1957.	1.5	11
46	Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein. Antiviral Therapy, 2005, 10, 671-80.	0.6	8
47	Feline Immunodeficiency Virus Plasma Load Reduction by a Retroinverso Octapeptide Reproducing the Trp-Rich Motif of the Transmembrane Glycoprotein. Antiviral Therapy, 2005, 10, 671-680.	0.6	14
48	The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology, 2004, 320, 156-166.	1.1	28
49	Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology, 2004, 322, 360-369.	1.1	11
50	Retroinverso Analogue of the Antiviral Octapeptide C8 Inhibits Feline Immunodeficiency Virus in Serum. Journal of Medicinal Chemistry, 2003, 46, 1807-1810.	2.9	12
51	Evolution of Two Amino Acid Positions Governing Broad Neutralization Resistance in a Strain of Feline Immunodeficiency Virus over 7 Years of Persistence in Cats. Vaccine Journal, 2003, 10, 1109-1116.	3.2	4
52	Antiviral Activity and Conformational Features of an Octapeptide Derived from the Membrane-Proximal Ectodomain of the Feline Immunodeficiency Virus Transmembrane Glycoprotein. Journal of Virology, 2003, 77, 3724-3733.	1.5	39
53	AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure To Protect and Possible Enhancement of Challenge Infection by Four Cell-Based Vaccines Prepared with Autologous Lymphoblasts. Journal of Virology, 2002, 76, 6882-6892.	1.5	29
54	Feline Immunodeficiency Virus-Infected Cat Sera Associated with the Development of Broad Neutralization Resistance In Vivo Drive Similar Reversions In Vitro. Journal of Virology, 2001, 75, 8868-8873.	1.5	8

#	Article	IF	Citations
55	During Readaptation In Vivo, a Tissue Culture-Adapted Strain of Feline Immunodeficiency Virus Reverts to Broad Neutralization Resistance at Different Times in Individual Hosts but through Changes at the Same Position of the Surface Glycoprotein. Journal of Virology, 2001, 75, 4584-4593.	1.5	25
56	AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Reevaluation of Neutralizing Antibody Levels Elicited by a Protective and a Nonprotective Vaccine after Removal of Antisubstrate Cell Antibodies. Journal of Virology, 2001, 75, 4424-4429.	1.5	13
57	Immunogenicity of an Anti-Clade B Feline Immunodeficiency Fixed-Cell Virus Vaccine in Field Cats. Journal of Virology, 2000, 74, 10911-10919.	1.5	28
58	AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine, 1999, 18, 119-130.	1.7	24
59	AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Detailed Analysis of the Humoral Immune Response to a Protective Vaccine. Journal of Virology, 1999, 73, 1-10.	1.5	21
60	Kinetics of Replication of a Partially Attenuated Virus and of the Challenge Virus during a Three-Year Intersubtype Feline Immunodeficiency Virus Superinfection Experiment in Cats. Journal of Virology, 1999, 73, 1518-1527.	1.5	20
61	Short Communication: Effect of Enzymatic Deglycosylation on Feline Immunodeficiency Virus Sensitivity to Antibody-Mediated Neutralization. AIDS Research and Human Retroviruses, 1998, 14, 199-204.	0.5	7
62	AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Homologous Erythrocytes as a Delivery System for Preferential Immunization with Putative Protective Antigens. Vaccine Journal, 1998, 5, 235-241.	2.6	15
63	Autologous and Heterologous Neutralization Analyses of Primary Feline Immunodeficiency Virus Isolates. Journal of Virology, 1998, 72, 2199-2207.	1.5	19
64	Sequence Note: Reduced Sensitivity to Strain-Specific Neutralization of Laboratory-Adapted Feline Immunodeficiency Virus after One Passage in Vivo: Association with Amino Acid Substitutions in the V4 Region of the Surface Glycoprotein. AIDS Research and Human Retroviruses, 1996, 12, 173-175.	0.5	19